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Monitoring adherence to drug treatment by using change in
cholesterol concentration: secondary analysis of trial data
Katy J L Bell, research academic,1 AdrienneKirby, biostatistician,2 AndrewHayen, senior lecturer, biostatistics,1
Les Irwig, professor of epidemiology,1 Paul Glasziou, director3
ABSTRACT
Objective To estimate the accuracy of monitoring
cholesterol concentration for detecting non-adherence to
lipid lowering treatment.
Design Secondary analysis of data on cholesterol
concentration in the LIPID (long term intervention with
pravastatin in ischaemic disease) study by using three
measures of non-adherence: discontinuation of
treatment, allocation to placebo arm, less than 80% of
pills taken.
Setting Randomised placebo controlled trial in Australia
and New Zealand.
Participants 9014 patients with previous coronary heart
disease.
Interventions Pravastatin 40 mg or placebo daily.
Main outcome measures Sensitivity, specificity, area
under the receiver operating characteristics (ROC) curve,
post-test probability.
ResultsMonitoring of cholesterol concentration had
modest ability for detecting complete non-adherence.
One year after the start of treatment, half (1957/3937) of
the non-adherent patients and 6% (253/3944) of
adherent patients had a rise in concentration of low
density lipoprotein cholesterol. Accuracy was reasonable
(area under the curve 0.89). Cholesterol monitoring,
however, had weak ability for detecting partial non-
adherence. One year after the start of treatment, 16% (34/
213) of partially adherent and 4% (155/3585) of fully
adherent patients had a rise in concentration of low
density lipoprotein cholesterol. Accuracy was poor (area
under the curve 0.65). For typical pre-test probabilities of
non-adherence ranging from low (25%) to high (75%), the
post-test probabilities indicate continuing uncertainty
after lipid testing. A patient with no change in low density
lipoprotein cholesterol concentration has a post-test
probability of being completely non-adherent of between
67% and 95% and a post-test probability of being
partially non-adherent of between 48% and 89%. A
patient with a decrease in concentration of 1.0 mmol/L
has a post-test probability of being completely non-
adherent of between 7% and 40% and a post-test
probability of being partially non-adherent of between
21% and 71%.
ConclusionsMonitoring concentration of low density
lipoprotein (or total) cholesterol has modest ability to
detect complete non-adherence or non-persistence with
pravastatin treatment and weak ability to detect partial
non-adherence. Results of monitoring should be
considered as no more than an adjunct to careful
discussion with patients about adherence.
INTRODUCTION
After starting patients on lipid lowering treatment, clin-
icians might monitor them for several reasons, not all
of which are evidence based.1 Some evidence supports
monitoring cholesterol concentration soon after the
start of treatment to check the initial response23 and
to evaluate long term trends.3 On the other hand, the
value of such monitoring to detect non-adherence
remains unproved. Despite this, several clinical guide-
lines recommend regular monitoring to assess and
improve adherence. The National Cholesterol Educa-
tion Program suggests that “Lipoprotein profiles
should be assessed at least annually, and preferably at
each clinic visit to promote compliance.”4 In the United
Kingdom, the NHS CKS (National Health System
Clinical Knowledge Summaries) recommend that clin-
icians can “review the lipid profile (e.g. to assess compli-
ance)” after starting patients on treatment for the
primary prevention of cardiovascular disease.5 In Aus-
tralia, the National Heart Foundation recommends
that “patients at high risk should have their lipid levels
measured every 6-12 months as part of the ongoing
assessment of adherence.”6
Non-adherence can be classified as partial or com-
plete—that is, continuing to take treatment but at a
dose that is considerably less than that prescribed, or
stopping taking treatment altogether (also referred to
as non-persistence).7 Though lipid lowering drugs such
as statins are generally well tolerated,8 non-adherence
is thought to be an important cause of decreased effec-
tiveness in the community.9 Non-adherence increases
with time from the start of treatment: the prevalence of
non-adherence to statin treatment in patients aged 65
or older was estimated as 29%, 38%, 42%, and 56%
after six months, one year, two years, and five years of
treatment.10 Different groups of patients have different
rates of non-adherence; at two years 75% of patients
prescribed a statin for primary prevention and 40% of
patients with an acute coronary syndrome were non-
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adherent.9 Many patients fail to take the full amount
prescribed: of those taking at least 20% of the drugs
prescribed to them, about four in 10 were taking less
than 80% of the drugs after one year.10
For patients to receive the full clinical benefits
observed in randomised trials, adherence to lipid low-
ering treatment needs to be maximised. For clinicians
to target interventions to increase adherence11 to
patients most in need, they need to be able to reliably
detect non-adherence. Methods to detect non-adher-
ence include “direct” methods such as directly
observed treatment and blood drug concentrations
and “indirect” methods such as questionnaires, pill
counts, prescription refill rates, measurement of
physiological markers (such as cholesterol concentra-
tion), and electronic medication monitoring.12
We evaluated the performance of monitoring cho-
lesterol concentration during the 12 months after the
start of treatment as a means of detecting non-adher-
ence to statin treatment.
METHODS
We analysed changes in cholesterol concentration
seen in the LIPID trial.13 Patients in that trial were eli-
gible if they had previous coronary heart disease and
had a plasma concentration of total cholesterol of 4.0-
7.0 mmol/L. After a dietary run-in period, they were
randomised to 40 mg of pravastatin or matching pla-
cebo. We compared adherent and “non-adherent”
patients in different ways.
Comparisons of “complete non-adherence”
To assess whether complete non-adherence could be
detected we used two groups:
Discontinuation—Among patients in the active treat-
ment group, we classified those who reported that they
were still taking any pills as “adherent” and those who
reported that they had stopped as “non-adherent.”
This is a direct method of comparing (partially or
fully) adherent with completely non-adherent patients.
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Fig 1 | Distribution of change in cholesterol concentration for permanent discontinuation of treatment before one year of follow-
up, randomisation to placebo, and taking less than 80% of prescribed tablets, without permanent discontinuation
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Placebo—Regardless of their actual level of compli-
ance, patients in the active treatment group were
classed as “adherent” and patients in the placebo
group were classed as “non-adherent.”This is an indir-
ect method of comparing completely adherent and
non-adherent patients in which the use of placebo is a
proxy for a non-adherent group of patients. The larger
number of non-adherent patients analysed with this
method allows for more robust statistical inferences
to be made.
Comparison of “partial non-adherence”
Pill count—To assess whether partial non-adherence
couldbedetectedwe classedpatients in the active treat-
ment groupwho continued taking at least some of their
pills as fully adherent if they took at least 80% (as
assessed by pill count at the six month visit) and as
partially non-adherent if they took less than 80%.
Only 9.4% (411) of the patients who did not perma-
nently stop their drugs took less than 80% of their
tablets.
Analyses
Our analyses were based on changes in cholesterol
(low density lipoprotein and total cholesterol) concen-
tration from the time of randomisation to 12 months
after randomisation. For each type of analysis we first
plotted the distribution of changes for adherent and
non-adherent patients. To determine the ability of the
change in cholesterol concentration to identify
whether a patient was from the adherent or non-adher-
ent groupof the trial we then plotted receiver operating
characteristics (ROC) curves. With this empirical
approach, the population levels of non-adherence
(pre-test probability) would be those of the trial setting,
and these are unlikely to reflect clinical populations
(for example, the placebo comparisonhas a population
level of non-adherence that is 50%, reflecting the 1:1
allocation of patients to active and placebo drugs).
Therefore, for each type of non-adherence we fitted
models that allowed for different population levels of
non-adherence. We estimated post-test probability of
non-adherence for levels of population non-adherence
that differed from those in the trial and were more
likely to reflect clinical populations: 25%, 40%, 50%,
60%, and 75%. See the appendix on bmj.com for full
details.
RESULTS
Comparisons of complete non-adherence
Discontinuation—Of the people randomised to active
treatment, 3944 hadmeasurements of low density lipo-
protein cholesterol at randomisation and at 12months.
Of these, 3.2% (n=128) reported that they had stopped
all randomised treatment by 12 months (table 1). The
mean reduction in low density lipoprotein cholesterol
for the discontinuers (non-adherent) was 0.07 mmol/L
(SD 0.78 mmol/L) compared with a reduction of
1.15 mmol/L (SD 0.67 mmol/L) in the group still tak-
ing treatment. Figure 1 shows the observed distribu-
tion of these changes in low density lipoprotein
cholesterol, indicating some overlap in the distribu-
tions. The area under the curve was 0.86 (95% confi-
dence interval 0.83 to 0.90), indicating reasonable
discrimination (table 2 and fig 2). Results were similar
for total cholesterol concentration.
Placebo—Of the 9014 patients randomised to active
or placebo, 7881 had measurements of low density
lipoprotein cholesterol at randomisation and at
12months.Of these, about half were in the active treat-
ment group and half in the placebo group (table 1).
The mean reduction in low density lipoprotein
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Fig 2 | Receiver operating characteristics curves for three measures of adherence: permanent
discontinuation of treatment before one year of follow-up; randomisation to placebo; taking
less than 80% of prescribed pills, without permanent discontinuation (actual data related to
sensitivities and specificities for illustrated cut points are given in table 3.
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cholesterol was 0.02 mmol/L (SD 0.61mmol/L) in the
placebo group and 1.11 mmol/L (SD 0.70 mmol/L) in
the active treatment group. Figure 1 shows the
observed distribution of these changes in low density
lipoprotein cholesterol, indicating some overlap in the
distributions.
The accuracy of detecting adherence depends on the
cut off used. If any rise in concentration of low density
lipoprotein cholesterol at 12 months was taken as an
indicator of complete non-adherence, the sensitivity
would be 50% and the specificity 94% (fig 2). That is,
of those who were completely non-adherent, 50%
would have recorded a rise in concentration (and
50% no change or a fall in concentration) at
12 months; but of those who were adherent some 6%
would have recorded an apparent increase in concen-
tration at 12months, despite them taking their drugs. If
a cut off of a reduction of more than 0.5 mmol/L is
used, the sensitivity improves to 82%but the specificity
drops to 83% (82% of completely non-adherent and
17% of adherent patients failed to have a reduction of
0.5 mmol/L or more). The sensitivity and specificity is
95% and 59%, respectively, for reductions of more
than 1.0 mmol/L and 98% and 29% for reductions of
more than 1.5mmol/L. Figure 2 shows estimates for all
possible cut-off values for change in low density lipo-
protein cholesterol at 12 months. The area under the
curve was 0.89 (0.88 to 0.89), similar to the permanent
discontinuation comparison and again indicating rea-
sonable discrimination (table 2). Similar results were
found for total cholesterol.
Comparison of partial non-adherence
Pill count—Of people who continued to take active
treatment, 3798 hadmeasurements of low density lipo-
protein cholesterol at randomisation and at 12months.
Of these, 5.6% (213) were taking less than 80% of their
pills by 12months (table 1). Themean reduction in low
density lipoprotein cholesterol for partial non-
adherers was 0.77 mmol/L (SD 0.79 mmol/L) com-
pared with 1.17 mmol/L (0.65 mmol/L) in the fully
adherent group. Figure 1 shows the observed distribu-
tion of these changes in low density lipoprotein
cholesterol, indicating substantial overlap in the distri-
butions.
If any rise in concentration of low density lipopro-
tein cholesterol at 12 months was taken as an indicator
of partial non-adherence, the sensitivity would be 16%
and the specificity 96% (fig 2). That is, of those who
were partially non-adherent, 16% would have
recorded a rise in concentration (and 84% no change
or a fall in concentration) at 12 months; but of those
who were fully adherent some 4% would have
recorded an apparent increase in concentration at
12 months, despite them taking all their treatment. If
a cut off of a reduction of more than 0.5 mmol/L is
used, the sensitivity improves to 37%but the specificity
drops to 86% (37% of partially non-adherent and 14%
of fully adherent individuals failed to have a reduction
of 0.5 mmol/L or more). For reductions of more than
1.0 mmol/L the sensitivity and specificity are 60% and
62%, respectively, and for reductions of more than
1.5 mmol/L these are 81% and 30%. Figure 2 shows
estimates for all possible cut-off values for change in
low density lipoprotein cholesterol at 12 months. The
area under the curve was 0.65 (0.61 to 0.70), indicating
only modest discrimination (table 2). Similar results
were found for total cholesterol.
Effects of different population frequency of non-adherence
The prevalence (pre-test probability) of non-adher-
ence found in the LIPID trial was about 3% for the dis-
continuation comparison, 50% for the placebo
comparison, and 6% for the pill count comparison,
but these levels are unlikely to reflect clinical practice.
Figure 3 shows the probability of detecting non-adher-
ence given different changes in concentration of low
density lipoprotein cholesterol for a range of back-
ground prevalences of non-adherence that can be
found in clinical populations. The population preva-
lences shown are broadly based on those reported in
the literature, with high levels of non-adherence for
people who have been taking treatment for over a
year and have not experienced a cardiovascular event
(75% non-adherence), low levels of non-adherence for
those who have recently had a cardiovascular event
(25% non-adherence), and intermediate levels of non-
adherence for those who are in between these two
groups of patient (40%, 50%, and 60%non-adherence).
For permanent discontinuation of treatment before
one year of follow-up and randomisation to placebo,
depending on the pre-test probability and the change
observed in cholesterol concentration, the post-test
probability might be sufficiently high or low to diag-
Table 1 | Summary statistics for mean change for three methods of measuring adherence
Reported non-
adherence*
Reduction in LDL cholesterol
(mmol/L)
Reduction in total cholesterol
(mmol/L)
No of patients Mean (SD) No of patients Mean (SD)
Permanent discontinuation
No 3816 1.15 (0.67) 3946 1.20 (0.75)
Yes 128 0.07 (0.78) 134 0.06 (0.85)
Placebo
No 3944 1.11 (0.70) 4080 1.16 (0.78)
Yes 3937 −0.02 (0.61) 4053 0.04 (0.70)
<80% pills taken
No 3585 1.17 (0.65) 3702 1.22 (0.73)
Yes 213 0.77 (0.79) 224 0.80 (0.86)
LDL=low density lipoprotein.
*Participants reported they had stopped all allocated treatment by 12 months.
Table 2 | Area under receiver operating characteristics curve
(95% confidence interval)* for each type of non-adherence
LDL cholesterol Total cholesterol
Permanent discontinuation 0.86 (0.83 to 0.90) 0.86 (0.82 to 0.89)
Placebo 0.89 (0.88 to 0.89) 0.87 (0.86 to 0.88)
<80% of pills taken 0.65 (0.61 to 0.70) 0.65 (0.61 to 0.69)
LDL=low density lipoprotein.
*All P<0.001
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nose, or rule out, complete non-adherence (fig 3).
Patientswith a pre-test probability of 75%and a change
in low density lipoprotein cholesterol of −1.5, −1.0,
−0.50, 0, and 0.50 mmol/L have post-test probabilities
of complete non-adherence of around 14%, 40%, 81%,
95%, and 97.5%, respectively. Patients with a pre-test
probability of 25% and a change in low density lipo-
protein cholesterol of −1.5, −1.0, −0.50, 0, and
0.50 mmol/L have post-test probabilities of complete
non-adherence of around 2%, 7%, 32%, 67%, and 76%,
respectively.
Figure 3 also shows that for those taking less than
80% of prescribed pills, without permanent disconti-
nuation, depending on the pre-test probability and
the change observed in cholesterol, the post-test prob-
ability might sometimes be sufficiently high to diag-
nose partial non-adherence. No matter what the pre-
test probability and change in cholesterol concentra-
tion observed, however, the post-test probability is
unlikely ever to be sufficiently low to rule out partial
non-adherence. Patients with a pre-test probability of
75% and a change in low density lipoprotein choles-
terol of −1.5, −1.0, −0.50, 0, and 0.50 mmol/L have
post-test probabilities of partial non-adherence of
around 64%, 71%, 82%, 89%, and 93%, respectively.
Patientswith a pre-test probability of 25%and a change
in low density lipoprotein cholesterol of −1.5, −1.0,
−0.50, 0, and 0.50 mmol/L have post-test probabilities
of partial non-adherence of around 16%, 21%, 34%,
48%, and 58%, respectively.
DISCUSSION
This analysis of data from the LIPID trial shows sub-
stantial overlap between the changes in cholesterol
concentration seen in patients receiving placebo com-
pared with those receiving a statin, and even greater
overlap between good and poor compliers. These find-
ings suggest that monitoring cholesterol concentration
ismodestly accurate in detecting patientswho are com-
pletely non-adherent or non-persistent with pravasta-
tin treatment. Cholesterol changes seem less useful in
detecting partial non-adherence. In both cases, low
density lipoprotein cholesterol concentration seems
slightly better than total cholesterol concentration at
detecting non-compliance. For typical pre-test prob-
abilities of non-adherence the post-test probabilities
indicate continuing uncertainty after lipid testing. A
patient with no change in low density lipoprotein cho-
lesterol has a post-test probability of between 67% and
95% for complete non-adherence and between 48%
and 89% for partial non-adherence. Hencemonitoring
is more useful for diagnosing non-adherence in popu-
lations where the background prevalence is high. Even
then a relatively extreme result of monitoring (no
change) is required to confirm partial non-adherence,
given that the average change in low density lipopro-
tein cholesterol for this group was a reduction of
around 0.8 mmol/l. A patient with a reduction of
1.0 mmol/L has a post-test probability of between 7%
and 40% for complete non-adherence and between
21% and 71% for partial non-adherence. Hence mon-
itoring might be useful for ruling out complete non-
adherence in populations where the background pre-
valence is low but is rarely likely to be useful for ruling
out partial non-adherence. Even with a pre-test prob-
ability of 25%and a decrease in lowdensity lipoprotein
cholesterol of 1.5 mmol/L, the post-test probability of
partial non-adherence is still relatively high at 16%.
Whenmonitoring patients on statins, clinicians should
be aware of this inaccuracy.
Strengths and limitations of study
There are some limitations of our study. Firstly, we
limited our analysis to 12 months, whereas clinicians
might assess adherence for longer periods of treatment.
Change in cholesterol concentration over a year after
the start of treatment is likely to perform less well for
detection of non-adherence. For longer term monitor-
ing, patients’ cholesterol concentrations show random
upward drift3 as a natural consequence of the ageing
process. Monitoring to detect non-adherence would
need to distinguish any change in cholesterol concen-
tration as a consequence of failure to take drugs from
the natural upward trend that occurs at different rates
between patients. Secondly, we labelled patients as
partially non-adherent if they took less than 80% of
their pills (this is a common definition used in
trials10 14). In clinical practice, however, definitions
might be less stringent—for example, partial non-
adherence might be defined as taking less than 50%
or an even lower percentage. Statins are relatively tol-
erant to partial compliance.Most of the effect of statins
is seen at low doses, with more marginal gains as the
dose is increased: doses that are about 25% of the
Table 3 | Sensitivities and specificities related for cut points illustrated in figure 2
0 mmol/L −0.5 mmol/L −1.0 mmol/L −1.5 mmol/L
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Change in low density lipoprotein concentration
Permanent discontinuation before 1 year 0.51 0.95 0.73 0.85 0.91 0.61 0.96 0.29
Randomised to placebo 0.50 0.94 0.82 0.83 0.95 0.59 0.98 0.29
<80% pills taken 0.16 0.96 0.75 0.84 0.60 0.62 0.81 0.30
Change in total cholesterol concentration
Permanent discontinuation before 1 year 0.48 0.94 0.75 0.84 0.90 0.63 0.95 0.34
Randomised to placebo 0.48 0.93 0.79 0.82 0.93 0.62 0.98 0.33
<80% pills taken 0.16 0.95 0.38 0.85 0.57 0.65 0.80 0.34
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maximum dose result in roughly 50% of the effect.15
Use of a less stringent definition of partial non-adher-
ence could mean that change in cholesterol concentra-
tion performs somewhat better than the estimates we
have given here. Even so, partial non-adherence is
likely to be substantially more difficult to detect than
complete non-adherence by use of clinic lipid mea-
surements. And yet it is for partial non-adherence
that a diagnostic test is most needed. Unlike comple-
tely non-adherent patients, who are likely to tell their
clinicians they have stopped taking the drug or simply
stop turning up to follow-up clinic appointments, par-
tially non-adherent patients might be reluctant to
volunteer information on their pill taking.
Conclusions and policy implications
Despite recommendations in clinical guidelines that
cholesterol concentration be monitored to detect
non-adherence, there is a surprising paucity of studies
that have examined the relation between change in
concentration and adherence. Change in concentra-
tion three months after the start of treatment has been
found to not only correlate with adherence at three
months but also adherence at later time points (even
after adjustment for adherence at three months). This
indicates that the relation is a bidirectional one: adher-
ence affects change in concentration and change in
concentration affects adherence.14 Although an appar-
ent drop in concentration seems to enhance adherence,
an apparent rise will tend to hinder it, and for some
patients monitoring cholesterol concentration might
actually have a negative impact on their future adher-
ence to treatment. This is in keeping with other
research showing decreased adherence to dietary
advice in patients found to have cholesterol concentra-
tions below a certain threshold.16 17
Interviewswithpatientshavealsobeen foundtopredict
adherence to treatment,18 and making patients an active
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Fig 3 | Post-test probability of non-adherence by change in cholesterol and pre-test probability (25%, 40%, 50%, 60%, or 75%)
for permanent discontinuation of treatment before 1 year of follow-up, randomisation to placebo, and taking less than 80% of
prescribed pills, without permanent discontinuation
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part of treatment decisions increases adherence.1920
Rather than a formal interview, a practical approach is
for clinicians to simplyask thepatient if sheorhe ishaving
problems adhering to treatment. This question needs to
be framed in a non-judgmental way that keeps the patient
at ease. One suggestion is to ask “I know it must be diffi-
cult to take all your medications regularly. How often do
youmiss taking them?”12 Other questions that could help
to identify poor adherence include asking the patient
whether they are having side effects from the drugs, why
they believe they are taking them, and what they believe
are the benefits of treatment.12
In conclusion, whilemonitoring cholesterol concen-
tration seems to be a somewhat useful method of
detecting complete non-adherence to cholesterol low-
ering treatment, it is less accurate for detecting partial
non-adherence and at most should be used as an
adjunct to careful questioning about problems with
adherence. Clinical practice guidelines need to be
updated to reflect the limitations of cholesterol mea-
surement as a means of detecting non-adherence and
make other recommendations about how this can be
achieved. Further research to identify effective ways of
detecting non-adherence with cholesterol concentra-
tion might include combining multiple types of
cholesterol measurement21 or multiple measurement
occasions, or both.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Adherence with lipid lowering treatment varies between patients
Guidelines recommend that clinicians monitor patients’ cholesterol concentrations to assess
adherence
The capacity of lipid monitoring to detect non-adherence is unknown
WHAT THIS STUDY ADDS
Monitoring low density lipoprotein (or total) cholesterol concentration has modest ability to
detect complete non-adherence or non-persistence with pravastatin treatment and weak
ability to detect partial non-adherence
Monitoring cholesterol concentration could serve as an adjunct to careful questioning about
problems with adherence
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